Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Peru

- PMLiVE

Takeda: No decision yet on shutdown of Cambridge, UK unit

Tells PMLiVE that consultation over proposed closure of R&D site still ongoing

- PMLiVE

NICE turns down CDF drug Adcetris in draft guidance

Takeda’s treatment for Hodgkin’s lymphoma not seen to be cost-effective

- PMLiVE

Takeda partners with Marvel for IBD superheroes

Will work with the entertainment firm's content marketing agency

- PMLiVE

Takeda hands back rights to two Amgen drugs

Returns pain and ovarian cancer candidates but will continue with collaboration

- PMLiVE

Takeda starts trial of norovirus vaccine

If approved the drug is anticipated to surpass sales of GSK’s Rotarix vaccine

- PMLiVE

Takeda forms new women’s health and cancer company

Recruits former Medivation CMO Lynn Seely to lead Myovant Sciences

Takeda appoints chief financial officer and corporate officer

James Kehoe takes on both roles from 15 June

UK Life Sciences Strategy - one year on

Astellas, Daiichi Sankyo and Takeda to study biomarkers

Collaboration aims to establish comprehensive database to accelerate drug development

- PMLiVE

Teva and Takeda appoint head of Japanese generics venture

Hiroshi Matsumori will lead partnership of Teva’s generics portfolio and Takeda brands

- PMLiVE

Forging a path in specialty care

Takeda’s Marc Princen on the company’s plans to build a reputation in oncology, gastroenterology and vaccine

China flag thumb

AstraZeneca sets sights on China with Takeda deal

Buys the Japanese firm's respiratory drugs to extends their ongoing biologics R&D collaboration

- PMLiVE

FDA clears Takeda’s oral multiple myeloma drug

Ninlaro is the first oral proteasome inhibitor to get a green light from the FDA

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links